A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 22 02 2022
revised: 09 05 2022
accepted: 22 05 2022
pubmed: 9 6 2022
medline: 29 6 2022
entrez: 8 6 2022
Statut: ppublish

Résumé

Many risk factors for the development of severe forms of Covid-19 have been identified, some applying to the general population and others specific to Multiple Sclerosis (MS) patients. However, a score for quantifying the individual risk of severe Covid-19 in patients with MS is not available. The aim of this study was to construct such score and to evaluate its performance. Data on patients with MS infected with Covid-19 in Italy, Turkey and South America were extracted from the Musc-19 platform. After imputation of missing values, data were separated into training data set (70%) and validation data set (30%). Univariable logistic regression models were performed in the training dataset to identify the main risk factors to be included in the multivariable logistic regression analyses. To select the most relevant variables we applied three different approaches: (1) multivariable stepwise, (2) Lasso regression, (3) Bayesian model averaging. Three scores were defined as the linear combination of the coefficients estimated in the models multiplied by the corresponding value of the variables and higher scores were associated to higher risk of severe Covid-19 course. The performances of the three scores were compared in the validation dataset based on the area under the ROC curve (AUC) and an optimal cut-off was calculated in the training dataset for the score with the best performance. The probability of showing a severe Covid-19 course was calculated based on the score with the best performance. 3852 patients were included in the study (2696 in the training dataset and 1156 in the validation data set). 17% of the patients required hospitalization and risk factors for severe Covid-19 course were older age, male sex, living in Turkey or South America instead of living in Italy, presence of comorbidities, progressive MS, longer disease duration, higher Expanded Disability Status Scale, Methylprednisolone use and anti-CD20 treatment. The score with the best performance was the one derived using the Lasso selection approach (AUC= 0.72) and it was built with the following variables: age, sex, country, BMI, presence of comorbidities, EDSS, methylprednisolone use, treatment. An excel spreadsheet to calculate the score and the probability of severe Covid-19 is available at the following link: https://osf.io/ac47u/?view_only=691814d57b564a34b3596e4fcdcf8580. The originality of this study consists in building a useful tool to quantify the individual risk for Covid-19 severity based on patient's characteristics. Due to the modest predictive ability and to the need of external validation, this tool is not ready for being fully used in clinical practice to make important decisions or interventions. However, it can be used as an additional instrument to identify high-risk patients and persuade them to take important measures to prevent Covid-19 infection (i.e. getting vaccinated against Covid-19, adhering to social distancing, and using of personal protection equipment).

Sections du résumé

BACKGROUND BACKGROUND
Many risk factors for the development of severe forms of Covid-19 have been identified, some applying to the general population and others specific to Multiple Sclerosis (MS) patients. However, a score for quantifying the individual risk of severe Covid-19 in patients with MS is not available. The aim of this study was to construct such score and to evaluate its performance.
METHODS METHODS
Data on patients with MS infected with Covid-19 in Italy, Turkey and South America were extracted from the Musc-19 platform. After imputation of missing values, data were separated into training data set (70%) and validation data set (30%). Univariable logistic regression models were performed in the training dataset to identify the main risk factors to be included in the multivariable logistic regression analyses. To select the most relevant variables we applied three different approaches: (1) multivariable stepwise, (2) Lasso regression, (3) Bayesian model averaging. Three scores were defined as the linear combination of the coefficients estimated in the models multiplied by the corresponding value of the variables and higher scores were associated to higher risk of severe Covid-19 course. The performances of the three scores were compared in the validation dataset based on the area under the ROC curve (AUC) and an optimal cut-off was calculated in the training dataset for the score with the best performance. The probability of showing a severe Covid-19 course was calculated based on the score with the best performance.
RESULTS RESULTS
3852 patients were included in the study (2696 in the training dataset and 1156 in the validation data set). 17% of the patients required hospitalization and risk factors for severe Covid-19 course were older age, male sex, living in Turkey or South America instead of living in Italy, presence of comorbidities, progressive MS, longer disease duration, higher Expanded Disability Status Scale, Methylprednisolone use and anti-CD20 treatment. The score with the best performance was the one derived using the Lasso selection approach (AUC= 0.72) and it was built with the following variables: age, sex, country, BMI, presence of comorbidities, EDSS, methylprednisolone use, treatment. An excel spreadsheet to calculate the score and the probability of severe Covid-19 is available at the following link: https://osf.io/ac47u/?view_only=691814d57b564a34b3596e4fcdcf8580.
CONCLUSIONS CONCLUSIONS
The originality of this study consists in building a useful tool to quantify the individual risk for Covid-19 severity based on patient's characteristics. Due to the modest predictive ability and to the need of external validation, this tool is not ready for being fully used in clinical practice to make important decisions or interventions. However, it can be used as an additional instrument to identify high-risk patients and persuade them to take important measures to prevent Covid-19 infection (i.e. getting vaccinated against Covid-19, adhering to social distancing, and using of personal protection equipment).

Identifiants

pubmed: 35675744
pii: S2211-0348(22)00420-5
doi: 10.1016/j.msard.2022.103909
pmc: PMC9130313
pii:
doi:

Substances chimiques

Methylprednisolone X4W7ZR7023

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103909

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Références

Stat Med. 2012 Oct 15;31(23):2676-86
pubmed: 22307964
Med Intensiva (Engl Ed). 2022 Feb;46(2):98-101
pubmed: 34896032
BMJ. 2015 Jan 07;350:g7594
pubmed: 25569120
Mult Scler Relat Disord. 2022 Jan;57:103358
pubmed: 35158467
Mult Scler Relat Disord. 2020 Oct;45:102359
pubmed: 32663793
Eur J Neurol. 2013 Aug;20(8):1153-60
pubmed: 23496086
Mult Scler Relat Disord. 2021 Nov;56:103324
pubmed: 34656933
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Nat Rev Neurol. 2016 Apr;12(4):217-33
pubmed: 26943779
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1):
pubmed: 34753829
Mult Scler Relat Disord. 2021 Oct;55:103173
pubmed: 34332462
PLoS One. 2020 Jul 30;15(7):e0236618
pubmed: 32730358
Mult Scler Relat Disord. 2022 Apr;60:103723
pubmed: 35276452
Rev Neurol (Paris). 2022 Jan-Feb;178(1-2):121-128
pubmed: 34836608
BMJ. 2009 May 28;338:b605
pubmed: 19477892
Front Med (Lausanne). 2021 Feb 18;8:608107
pubmed: 33681245

Auteurs

Marta Ponzano (M)

Department of Health Sciences, University of Genoa, Genoa, Italy. Electronic address: ponzano.marta@gmail.com.

Irene Schiavetti (I)

Department of Health Sciences, University of Genoa, Genoa, Italy.

Francesca Bovis (F)

Department of Health Sciences, University of Genoa, Genoa, Italy.

Doriana Landi (D)

Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy.

Luca Carmisciano (L)

Department of Health Sciences, University of Genoa, Genoa, Italy.

Nicola De Rossi (N)

Centro Sclerosi Multipla ASST Spedali Civili di Brescia, Montichiari, Italy.

Cinzia Cordioli (C)

Centro Sclerosi Multipla ASST Spedali Civili di Brescia, Montichiari, Italy.

Lucia Moiola (L)

Department of Neurology, Multiple Sclerosis Center, IRCCS Ospedale San Raffaele, Milan, Italy.

Marta Radaelli (M)

Department of Neurology and Multiple Sclerosis Center, ASST "Papa Giovanni XXIII", Bergamo, Italy.

Paolo Immovilli (P)

Multiple Sclerosis Center, Ospedale Guglielmo da Saliceto, Piacenza, Italy.

Marco Capobianco (M)

Regional Referral Multiple Sclerosis Centre, Department of Neurology, University Hospital San Luigi, Orbassano, Torino, Italy.

Margherita Monti Bragadin (MM)

AISM Rehabilitation Center, Italian MS Society, Genoa, Italy.

Eleonora Cocco (E)

Centro Sclerosi Multipla, ATS Sardegna, Cagliari, Italy.

Cinzia Scandellari (C)

IRCCS Istituto delle Scienze Neurologiche di Bologna, UOSI Riabilitazione Sclerosi Multipla, Bologna, Italy.

Paola Cavalla (P)

MS Center, Department of Neuroscience, City of Health and Science University Hospital of Turin, Turin, Italy.

Ilaria Pesci (I)

Centro SM UOC Neurologia, Fidenza, AUSL PR, Fidenza, Italy.

Paolo Confalonieri (P)

Multiple Sclerosis Centre, Neuroimmunology Department 'Carlo Besta' Neurological Institute, Milan, Italy.

Paola Perini (P)

Department of Neurology Multiple Sclerosis Center, University of Padua, Padova, Italy.

Roberto Bergamaschi (R)

Multiple Sclerosis Research Center, IRCCS Mondino Foundation, Pavia, Italy.

Matilde Inglese (M)

Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Maria Petracca (M)

Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy; Department of Human Neurosciences, Sapienza University, Rome, Italy.

Maria Trojano (M)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.

Gioacchino Tedeschi (G)

Department of Advanced Medical and Surgical Sciences, University of Campania "L. Vanvitelli", Naples, Italy.

Giancarlo Comi (G)

Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, Milano.

Mario Alberto Battaglia (MA)

Research Department, Italian Multiple Sclerosis Foundation, Genoa, Italy; Department of Life Sciences, University of Siena, Italy.

Francesco Patti (F)

Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania; Centro Sclerosi Multipla, Policlinico Catania, University of Catania.

Yara Dadalti Fragoso (YD)

Post Graduate Studies, Universidade Metropolitana de Santos, Santos, SP, Brazil.

Sedat Sen (S)

Ondokuz Mayis University School of Medicine Samsun, Turkey.

Aksel Siva (A)

Istanbul University Cerrahpasa School of Medicine Istanbul, Turkey.

Rana Karabudak (R)

Hacettepe University School of Medicine Ankara, Turkey.

Husnu Efendi (H)

Kocaeli University School of Medicine Kocaeli, Turkey.

Roberto Furlan (R)

Division of Neuroscience, Italian Neuroimmunology Association-AINI, IRCCS Ospedale San Raffaele, Institute of Experimental Neurology, Milano, Italy.

Marco Salvetti (M)

Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy; Unit of Neurology, IRCCS Neuromed, Pozzilli, Isernia, Italy.

Maria Pia Sormani (MP)

Department of Health Sciences, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH